Animas Corporation launches the IR 1250 Insulin Infusion Pump, the fir

    Business Editors/Health/Medical Writers

    WEST CHESTER, Pa.--(BUSINESS WIRE)--Jan. 26, 2005--Animas Corporation (NASDAQ:PUMP), a leading manufacturer of insulin pumps, announced today the launch of its newest insulin pump, the Animas IR 1250 in the first half of February 2005.
    The IR 1250 is another step towards Animas' quest to make diabetes management easier. Specifically, the product incorporates a food database of up to 500 items, consisting of customized items entered by the patient and/or items chosen by patients from the popular CalorieKing 3,000 food-item database. Intensive management of diabetes requires that people with diabetes administer insulin to compensate for carbohydrates ingested. The IR 1250's incorporation of a food database reduces patient's guesswork when counting carbohydrates, allowing for more accurate dosing of insulin.
    Another new feature of the IR 1250 is the incorporation of tunes for alerts. Patients can customize audio notification for alerts with their own compositions or choose from popular songs. The IR 1250 will also allow patients or healthcare providers to enter sick-day tips to their pump to help control diabetes during times of illness.
    The IR 1250 follows in the footsteps of earlier generations of Animas pumps with its waterproof integrity, ease of use, long battery life and advanced features for more precise insulin delivery.
    According to Dr. Katherine Crothall, CEO and President, "Many people with diabetes struggle with carbohydrate counting, and either find it very time-consuming or do a less-than-accurate job with it. Having an extensive food database incorporated in our pump is an important step forward in pump therapy. We are also very pleased to break ground with the incorporation of customized tunes. Many people, particularly teenagers, wish to be discreet with their diabetes, and using tunes in lieu of beeps help them achieve this goal. Our IR 1250 pump not only looks like a small cell phone, but it now sounds like one as well."
    "We continue to strive for greater advancements in diabetes management as reflected in our recent acquisition of our MicroPump(TM) and MicroNeedle(TM) technology from Debiotech, S.A. Our significant progress in developing a more accurate continuous glucose sensor, our continued advancements in insulin pump development, and our micro technology take us yet another step closer towards a viable closed loop system," Dr. Crothall notes.
    About Animas Corporation: Animas, a leading maker of insulin infusion pumps and related products, is dedicated to improving diabetes management and making insulin pump therapy easier for patients with insulin requiring diabetes and healthcare professionals through product innovation, exemplary customer support and superior customer education. For more information on Animas, visit http://www.animascorp.com or call Animas Corporation at 877-937-7867.

    Statements in this press release or made by management from time to time regarding Animas Corporation that are not historical facts are forward-looking statements and are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The following factors, among others, could cause Animas' actual results to differ materially from those described in a forward-looking statement: the failure to successfully commercialize the licensed technology, technical issues or the failure of the IR 1250 to gain significant market acceptance; failure to capture recurring purchases of ancillary supplies by patients using Animas' pumps; any significant disruption with vendors; any failure to achieve and then maintain profitability; the failure of Animas' ezSet Infusion Set to be fully-developed or commercially accepted; technological breakthroughs in diabetes monitoring, treatment, or prevention that could render Animas' products obsolete; failure to comply with any FDA or foreign regulations; an inability to attract and retain personnel; competition; an inability to adequately protect Animas' intellectual property; product liability lawsuits; and, the failure to secure or retain third party insurance coverage or reduced reimbursement for Animas' products by third party payors. This list is intended to identify only certain of the principal factors that could cause actual results to differ. Readers are referred to the reports and documents filed from time to time by Animas Corporation with the Securities and Exchange Commission for a discussion of these and other important risk factors. Readers are cautioned not to place undue reliance on forward-looking statements, which are made as of the date of this press release. Animas Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or for any other reason.

--30--SF/ph*

CONTACT: Animas Corporation Richard Baron, 610-644-8990 richard.baron@animascorp.com

KEYWORD: PENNSYLVANIA INDUSTRY KEYWORD: MEDICAL MEDICAL DEVICES PRODUCT SOURCE: Animas Corporation

Copyright Business Wire 2005